Press Room

Radnor, PA, June 2, 2010: QR Pharma, Inc., a specialty pharmaceutical company focused on developing novel therapeutics for the treatment of Alzheimer’s disease, announced today a $500,000 investment from BioAdvance and additional funding from Angel Investors. These investments closed a total of $2.4 million seed round, which QR opened a year ago, including BenFranklin Technology […]

Berwyn, PA, February 3, 2015 – QR Pharma, Inc.(QR) announced today a new collaborative research agreement with The Rockefeller University aimed at developing a treatment for Huntington’s disease (HD). The collaborationwill focus onpreclinical research involvingQR’s lead drug candidate, Posiphen®. Investigators at Rockefeller will conduct experiments in stem cell culture models of HD to determine if

Berwyn, PA, March 6, 2012 QR Pharma, Inc.(QR), a clinical stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of Alzheimer’s disease, Parkinson’s disease (PD) and other neurodegenerative disorders, announced today that The Michael J. Fox Foundation for Parkinson’s Research (MJFF) awarded the company $468,000 to conduct research for the

Berwyn, PA, July 24, 2012: QR Pharma, Inc. (QR), a clinical stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative disorders, announced today that it initiated the first human clinical trial of the company’s compound bisnorcymserine (BNC) to evaluate safety

Berwyn, Pa., January 6, 2015: QR Pharma, Inc., a privately held biopharmaceutical company developing novel therapies for the treatment of Alzheimer’s, Parkinson’s and other neurodegenerative diseases, announced the election of Mr. Michael Hoffman as Chairman of the Board of Directors and Mr. Dhesh Govender as Director. These appointments follow the recent opening of a Series